Literature DB >> 24067373

Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation.

Marco Pieraccioli1, Francesca Imbastari, Alexey Antonov, Gerry Melino, Giuseppe Raschellà.   

Abstract

Tumor progression to metastasis is a complex, sequential process that requires proliferation, resistance to apoptosis, motility and invasion to colonize at distant sites. The acquisition of these features implies a phenotypic plasticity by tumor cells that must adapt to different conditions by modulating several signaling pathways (1) during the journey to the final site of metastasis. Several transcription factors and microRNA play a role in tumor progression, but less is known about the control of their expression during this process. Here, we demonstrate by ectopic expression and gene silencing that the proto-oncogene c-Myb activates the expression of the 5 members of miR200 family (miR200b, miR200a, miR429, miR200c and miR141) that are involved in the control of epithelial-mesenchymal transition (EMT) and metastasis in many types of cancers. Transcriptional activation of miR200 by c-Myb occurs through binding to myb binding sites located in the promoter regions of miR200 genes on human chromosomes 1 and 12. Furthermore, when c-Myb and the transcriptional repressor ZEB1 are co-expressed, as at the onset EMT, the repression by ZEB1 prevails over the activation by c-Myb, and the expression of miR200 is inhibited. We also demonstrate that during EMT induced by TGF-β, the promoters of miR200 genes are methylated, and their transcription is repressed regardless of the presence of repressors such as ZEB1 and activators such as c-Myb. Finally, we find a correlation between the expression of c-Myb and that of four out of 5 miR200 in a data set of 207 breast cancer patients.

Entities:  

Keywords:  EMT; ZEB1; breast cancer; c-Myb; metastasis; miR200

Mesh:

Substances:

Year:  2013        PMID: 24067373      PMCID: PMC3755081          DOI: 10.4161/cc.25405

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  55 in total

Review 1.  Tumor metastasis: molecular insights and evolving paradigms.

Authors:  Scott Valastyan; Robert A Weinberg
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

2.  Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.

Authors:  Idoya Lahortiga; Kim De Keersmaecker; Pieter Van Vlierberghe; Carlos Graux; Barbara Cauwelier; Frederic Lambert; Nicole Mentens; H Berna Beverloo; Rob Pieters; Frank Speleman; Maria D Odero; Marijke Bauters; Guy Froyen; Peter Marynen; Peter Vandenberghe; Iwona Wlodarska; Jules P P Meijerink; Jan Cools
Journal:  Nat Genet       Date:  2007-04-15       Impact factor: 38.330

3.  Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis.

Authors:  Jeff H Tsai; Joana Liu Donaher; Danielle A Murphy; Sandra Chau; Jing Yang
Journal:  Cancer Cell       Date:  2012-11-29       Impact factor: 31.743

4.  Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).

Authors:  Cristina Oliveras-Ferraros; Bruna Corominas-Faja; Sílvia Cufí; Alejandro Vazquez-Martin; Begoña Martin-Castillo; Juan Manuel Iglesias; Eugeni López-Bonet; Ángel G Martin; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-09-19       Impact factor: 4.534

5.  Transcription factor c-Myb is involved in the regulation of the epithelial-mesenchymal transition in the avian neural crest.

Authors:  V Karafiat; M Dvorakova; E Krejci; J Kralova; P Pajer; P Snajdr; S Mandikova; P Bartunek; M Grim; M Dvorak
Journal:  Cell Mol Life Sci       Date:  2005-11       Impact factor: 9.261

6.  Critical functions for c-Myb at three checkpoints during thymocyte development.

Authors:  Timothy P Bender; Christopher S Kremer; Manfred Kraus; Thorsten Buch; Klaus Rajewsky
Journal:  Nat Immunol       Date:  2004-06-13       Impact factor: 25.606

7.  The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children.

Authors:  Emmanuelle Clappier; Wendy Cuccuini; Anna Kalota; Antoine Crinquette; Jean-Michel Cayuela; Willem A Dik; Anton W Langerak; Bertrand Montpellier; Bertrand Nadel; Pierre Walrafen; Olivier Delattre; Alain Aurias; Thierry Leblanc; Hervé Dombret; Alan M Gewirtz; André Baruchel; Francois Sigaux; Jean Soulier
Journal:  Blood       Date:  2007-04-23       Impact factor: 22.113

8.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.

Authors:  Li Ma; Julie Teruya-Feldstein; Robert A Weinberg
Journal:  Nature       Date:  2007-09-26       Impact factor: 49.962

9.  Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.

Authors:  Manav Korpal; Brian J Ell; Francesca M Buffa; Toni Ibrahim; Mario A Blanco; Toni Celià-Terrassa; Laura Mercatali; Zia Khan; Hani Goodarzi; Yuling Hua; Yong Wei; Guohong Hu; Benjamin A Garcia; Jiannis Ragoussis; Dino Amadori; Adrian L Harris; Yibin Kang
Journal:  Nat Med       Date:  2011-08-07       Impact factor: 53.440

10.  Analysis of microRNA turnover in mammalian cells following Dicer1 ablation.

Authors:  Michael P Gantier; Claire E McCoy; Irina Rusinova; Damien Saulep; Die Wang; Dakang Xu; Aaron T Irving; Mark A Behlke; Paul J Hertzog; Fabienne Mackay; Bryan R G Williams
Journal:  Nucleic Acids Res       Date:  2011-03-29       Impact factor: 16.971

View more
  25 in total

1.  Transcription Factor Hepatocyte Nuclear Factor-1β (HNF-1β) Regulates MicroRNA-200 Expression through a Long Noncoding RNA.

Authors:  Sachin S Hajarnis; Vishal Patel; Karam Aboudehen; Massimo Attanasio; Patricia Cobo-Stark; Marco Pontoglio; Peter Igarashi
Journal:  J Biol Chem       Date:  2015-08-19       Impact factor: 5.157

2.  O-Linked N-Acetylglucosamine (O-GlcNAc) Expression Levels Epigenetically Regulate Colon Cancer Tumorigenesis by Affecting the Cancer Stem Cell Compartment via Modulating Expression of Transcriptional Factor MYBL1.

Authors:  Huabei Guo; Bing Zhang; Alison V Nairn; Tamas Nagy; Kelley W Moremen; Phillip Buckhaults; Michael Pierce
Journal:  J Biol Chem       Date:  2017-01-17       Impact factor: 5.157

Review 3.  Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer.

Authors:  Caroline Moyret-Lalle; Emmanuelle Ruiz; Alain Puisieux
Journal:  World J Clin Oncol       Date:  2014-08-10

4.  MicroRNA-141 protects PC12 cells against hypoxia/reoxygenation-induced injury via regulating Keap1-Nrf2 signaling pathway.

Authors:  Bin Zhou; Hong-Yun Liu; Bao-Lian Zhu; Ai-Xia Yue
Journal:  J Bioenerg Biomembr       Date:  2019-07-04       Impact factor: 2.945

Review 5.  miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.

Authors:  Merve Mutlu; Umar Raza; Özge Saatci; Erol Eyüpoğlu; Emre Yurdusev; Özgür Şahin
Journal:  J Mol Med (Berl)       Date:  2016-04-20       Impact factor: 4.599

6.  Notch1 Pathway Activation Results from the Epigenetic Abrogation of Notch-Related MicroRNAs in Mycosis Fungoides.

Authors:  Fernando Gallardo; Juan Sandoval; Angel Díaz-Lagares; Ricard Garcia; Teresa D'Altri; Jessica González; Victor Alegre; Octavio Servitje; Ana-Belén Crujeiras; Ólafur-Andri Stefánsson; Blanca Espinet; Maria-Inmaculada Hernández; Beatriz Bellosillo; Manel Esteller; Ramon-Maria Pujol; Anna Bigas; Lluis Espinosa
Journal:  J Invest Dermatol       Date:  2015-08-24       Impact factor: 8.551

Review 7.  MiR-200, a new star miRNA in human cancer.

Authors:  Xiangling Feng; Zhengming Wang; Rebecca Fillmore; Yaguang Xi
Journal:  Cancer Lett       Date:  2013-11-19       Impact factor: 8.679

8.  miR-639 Expression Is Silenced by DNMT3A-Mediated Hypermethylation and Functions as a Tumor Suppressor in Liver Cancer Cells.

Authors:  Jing Xiao; Yankun Liu; Fuxia Wu; Ruiyan Liu; Yongli Xie; Qian Yang; Yufeng Li; Min Liu; Shengping Li; Hua Tang
Journal:  Mol Ther       Date:  2019-11-28       Impact factor: 11.454

9.  ZNF281 contributes to the DNA damage response by controlling the expression of XRCC2 and XRCC4.

Authors:  M Pieraccioli; S Nicolai; A Antonov; J Somers; M Malewicz; G Melino; G Raschellà
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

10.  ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling.

Authors:  Steven Goossens; Enrico Radaelli; Odile Blanchet; Kaat Durinck; Joni Van der Meulen; Sofie Peirs; Tom Taghon; Cedric S Tremblay; Magdaline Costa; Morvarid Farhang Ghahremani; Jelle De Medts; Sonia Bartunkova; Katharina Haigh; Claire Schwab; Natalie Farla; Tim Pieters; Filip Matthijssens; Nadine Van Roy; J Adam Best; Kim Deswarte; Pieter Bogaert; Catherine Carmichael; Adam Rickard; Santi Suryani; Lauryn S Bracken; Raed Alserihi; Kirsten Canté-Barrett; Lieven Haenebalcke; Emmanuelle Clappier; Pieter Rondou; Karolina Slowicka; Danny Huylebroeck; Ananda W Goldrath; Viktor Janzen; Matthew P McCormack; Richard B Lock; David J Curtis; Christine Harrison; Geert Berx; Frank Speleman; Jules P P Meijerink; Jean Soulier; Pieter Van Vlierberghe; Jody J Haigh
Journal:  Nat Commun       Date:  2015-01-07       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.